Spinal Muscular Atrophy Market expected to reach US$ 2.5 Billion by 2026, Finds Coherent Market Insights
SEATTLE, April 08, 2021, (PHARMIWEB) — Global Spinal Muscular Atrophy Market
Spinal muscular atrophy (SMA) is a genetic disorder that affects the regulation of muscle movement. It is caused due to the loss of specialized nerve cells, called motor neurons, in the spinal cord and brainstem. The loss of motor neurons leads to weakness and atrophy of muscles used for activities such as sitting up, walking, crawling, and controlling head movement. In severe cases, the muscles used for swallowing and breathing are also affected. There are four types of spinal muscular atrophy, which are differentiated on the basis of the severity of muscle weakness, pattern of features, and age. These are classified as type 1, 2, and 3 that appears in childhood. It is said that Type 4 appears during adulthood and is also termed as adult onset SMA.
The global spinal muscular atrophy market was pegged at US$ 884 million in 2017 and is expected to witness a robust CAGR of 12.4% over the forecast period (2018-2026).
Figure 1. Global Spinal Muscular Atrophy Market Share (%), By Age
Source: Coherent Market Insights Analysis (2018)
*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1920
Increasing number of clinical trials and government funding for R&D foreseen to bolster market growth
Various government and private organizations are investing huge capital and resources towards the development of new and effective therapies for spinal muscular atrophy. For instance, in 2015, the SMA Foundation financed over US$ 60 million in drug development programs and essential drug discovery assets that aim to develop an effective SMA therapy. In 2013, Cure SMA granted fund to Cytokinetics for the study of Tirasemtiv for SMA. Financial details of the grant were not disclosed. Tirasemtiv is a novel skeletal muscle activator and a lead drug candidate from Cytokinetics’ skeletal muscle contractility program. It has been studied in clinical trials for individuals with amyotrophic lateral sclerosis (ALS). Similar to SMA, ALS is also known for affecting motor neurons.
The National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institutes of Health (NIH), conducts clinical, translational, and basic research on SMA and further supports research through grants to major medical institutions across the U.S. In 2011, the authority established NeuroNext clinical trials network to promote rapid development and implementation of trials for neurological disorders that affect adults and/or children. The network is designed to develop early-phase trials aimed at identifying biomarkers that can be measured to determine the presence and severity of a disease, and
Growing incidence rate of spinal muscular atrophy anticipated to augment market growth
Spinal muscular atrophy usually manifests at an early age and therefore, is a major genetic cause of death in infants. It is one of the most common rare diseases. According to the SMA Foundation 2015 statistics, spinal muscular atrophy has generally been believed to affect as many as 10,000 to 25,000 adults and children in the U.S. In March 2018, CureSMA stated that SMA affects around 1 in 11,000 children, and 1 in 50 is a carrier of the disease. It has been found in people of every race, however, is most common in Caucasians, of whom 1 in 35 is a carrier. Spinal muscular atrophy carrier rates for other populations include Asians (1 in 53), African Americans (1 in 66), and Hispanics (1 in 117).
However, high costs of therapy can confine the growth of the spinal muscular atrophy market during the forecast period. For instance, Biogen’s Spinraza (nusinersen) drug for spinal muscular atrophy is estimated to cost US$ 125,000 per injection, accounting for US$ 750,000 for the first year and US$ 375,000 later.
Figure 2. Spinal Muscular Atrophy Therapy Pipeline, 2017
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/spinal-muscular-atrophy-market-to-reach-beyond-us-25-billion-by-2026-1000
Leading Market Players
The major players operating in the global spinal muscular atrophy market include Biogen, Cytokinetics, Inc., F. Hoffmann-La Roche, Novartis AG, Pfizer Inc., and Ionis Pharmaceuticals, Inc.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Technology
- Market Snippet, By Disease Indication
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- Pricing Analysis
- Clinical Trials For Spinal Muscular Atrophy
- Regulatory Landscape
- Reimbursement Scenario
- Pipeline Analysis
- Epidemiology
- PEST Analysis
- Market Dynamics
- Global Spinal Muscular Atrophy Market, By Disease Type, 2016–2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Type I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
- Type II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
- Type III
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
- Type IV
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
- Introduction
- Global Spinal Muscular Atrophy Market, By Treatment, 2016–2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
- Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
- Introduction
- Global Spinal Muscular Atrophy Market, By Age, 2016–2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Infant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Million)
- Introduction
- Global Spinal Muscular Atrophy Market, By Region, 2016 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2026
- North America
- Market Size and Forecast, By Disease Type, 2016–2026, (US$ Million)
- Market Size and Forecast, By Treatment, 2016–2026, (US$ Million)
- Market Size and Forecast, By Age, 2016–2026, (US$ Million)
- Market Size and Forecast, By Country, 2016–2026, (US$ Million)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Disease Type, 2016–2026, (US$ Million)
- Market Size and Forecast, By Treatment, 2016–2026, (US$ Million)
- Market Size and Forecast, By Age, 2016–2026, (US$ Million)
- Market Size and Forecast, By Country, 2016–2026, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Disease Type, 2016–2026, (US$ Million)
- Market Size and Forecast, By Treatment, 2016–2026, (US$ Million)
- Market Size and Forecast, By Age, 2016–2026, (US$ Million)
- Market Size and Forecast, By Country, 2016–2026, (US$ Million)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Disease Type, 2016–2026, (US$ Million)
- Market Size and Forecast, By Treatment, 2016–2026, (US$ Million)
- Market Size and Forecast, By Age, 2016–2026, (US$ Million)
- Market Size and Forecast, By Country, 2016–2026, (US$ Million)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Disease Type, 2016–2026, (US$ Million)
- Market Size and Forecast, By Treatment, 2016–2026, (US$ Million)
- Market Size and Forecast, By Age, 2016–2026, (US$ Million)
- Market Size and Forecast, By Country, 2016–2026, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Disease Type, 2016–2026, (US$ Million)
- Market Size and Forecast, By Treatment, 2016–2026, (US$ Million)
- Market Size and Forecast, By Age, 2016–2026, (US$ Million)
- Market Size and Forecast, By Country, 2016–2026, (US$ Million)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1920
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
